b-Arrestins in the Central Nervous System - Progress in Molecular Biology and Translational Science - page 281

54. Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS. In vivo regulation of
glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain.
Neuropsychopharmacology . 2004;29(8):1426 - 1431.
55. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor
A. EMBO J . 1990;9(8):2431 - 2438.
56. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery.
Biochem J . 2001;359(Pt. 1):1- 16.
57. Yamada T, Katagiri H, Asano T, et al. Role of PDK1 in insulin-signaling pathway for
glucose metabolism in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab . 2002;282(6):
E1385 - E1394.
58. Altar CA, Hunt RA, Jurata LW, et al. Insulin, IGF-1, and muscarinic agonists modulate
schizophrenia-associated genes in human neuroblastoma cells. Biol Psychiatry . 2008;64
(12):1077 - 1087.
59. Woodgett JR. Regulation and functions of the glycogen synthase kinase-3 subfamily.
Semin Cancer Biol . 1994;5(4):269 - 275.
60. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust . 1949;2
(10):349 - 352.
61. Schou M, Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses
by the administration of lithium salts. J Neurol Neurosurg Psychiatry . 1954;17(4):250 - 260.
62. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol .
2001;41:789 - 813.
63. Blanco C, Laje G, OlfsonM, Marcus SC, Pincus HA. Trends in the treatment of bipolar
disorder by outpatient psychiatrists. Am J Psychiatry . 2002;159(6):1005 - 1010.
64. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activ-
ity and mimics wingless signalling in intact cells. Curr Biol . 1996;6(12):1664 - 1668.
65. O'Brien WT, Klein PS. Validating GSK3 as an in vivo target of lithium action. Biochem
Soc Trans . 2009;37(Pt. 5):1133 - 1138.
66. Beaulieu JM, Marion S, Rodriguiz RM, et al. A beta-arrestin 2 signaling complex
mediates lithium action on behavior. Cell . 2008;132(1):125 - 136.
67. Pan JQ, LewisMC,Ketterman JK, et al.AKTkinase activity is required for lithiumtomod-
ulate mood-related behaviors in mice. Neuropsychopharmacology . 2011;36(7):1397 - 1411.
68. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate
inhibits the activity of glycogen synthase kinase-3. J Neurochem . 1999;72(3):1327 - 1330.
69. Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3beta, mood stabilizers, and
neuroprotection. Bipolar Disord . 2002;4(2):137 - 144.
70. Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lith-
ium mimetic drugs. Neuropsychopharmacology . 2005;30(7):1223- 1237.
71. Bohn LM, Schmid CL. Serotonin receptor signaling and regulation via beta-arrestins.
Crit Rev Biochem Mol Biol . 2010;45(6):555- 566.
72. Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and
anxious states: focus on novel therapeutic strategies. Therapie . 2005;60(5):441 - 460.
73. Iwamoto K, Bundo M, Kato T. Serotonin receptor 2C and mental disorders: genetic,
expression and RNA editing studies. RNA Biol . 2009;6(3):248 - 253.
74. Jakab RL, Goldman-Rakic PS. 5-Hydroxytryptamine2A serotonin receptors in the
primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs
in pyramidal cell apical dendrites. Proc Natl Acad Sci USA . 1998;95(2):735 - 740.
75. Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacology .
1999;21(2 Suppl.):16S - 23S.
76. Nichols DE. Hallucinogens. Pharmacol Ther . 2004;101(2):131- 181.
77. Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-
dopamine antagonist antipsychotics. J Clin Psychopharmacol . 1995;15(1 Suppl. 1):2S - 3S.